viewSeelos Therapeutics

Seelos Therapeutics earns patent approval for its neuromuscular disease drug

SLS-005 treats Friedreich Ataxia, a hereditary nervous system disease

Brain graphic
The New York-based company is focused on developing treatments for central nervous system and other rare disorders

Seelos Therapeutics Inc (NASDAQ:SEEL), a clinical stage biopharmaceutical company, has earned approval on its patent application for its drug, SLS-005.

The US Patent and Trademark Office issued a Notice of Allowance for the drug, which treats the hereditary neuromuscular disease Friedreich Ataxia.

The disease affects the nervous system, causing balance issues, spinal deformities and cardiovascular difficulty. It affects about one in 50,000 people worldwide.

READ: Seelos Therapeutics added to the Russell Microcap Index

SLS-005 already has orphan indication from the Food and Drug Administration for Spinocerebellar Ataxia, a related degenerative nervous system disease, and the company is developing the drug as a treatment for Sanfilippo syndrome.

Seelos Therapeutics is a New York-based company focused on developing treatments for central nervous system and other rare disorders. Its shares increased 0.5% Tuesday afternoon to $2.16.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Seelos Therapeutics

Price: 1.17 USD

Market: NASDAQ
Market Cap: $52.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...



Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read